Home » ETF » BIB

BIB - ProShares Ultra Nasdaq Biotechnology

Stock Price: $87.12 USD -1.06 (-1.20%)
Updated Apr 22, 2021 10:24 AM EDT - Market open
Assets $203.60M
NAV $84.83
Expense Ratio 0.95%
PE Ratio n/a
Beta (5Y) 1.99
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Sep 21, 2010
1-Year Return -
Trading Day April 22
Last Price $87.12
Previous Close $88.18
Change ($) -1.06
Change (%) -1.20%
Day's Open 87.50
Day's Range 86.08 - 87.90
Day's Volume 21,843
52-Week Range 56.19 - 113.06

Fund Description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Asset Class
North America
Inception Date
Apr 8, 2010
Ticker Symbol
Index Tracked
NASDAQ Biotechnology Index

Top 10 Holdings

132.35% of assets
Nasdaq Biotechnology Index Swap Societe Generale603698.SS26.92%
Nasdaq Biotechnology Index Swap Ubs Ag603698.SS25.08%
Nasdaq Biotechnology Index Swap Citibank Na603698.SS12.91%
Ishares Biotech (Ibb) Swap Goldman Sachs International603698.SS11.73%
Nasdaq Biotechnology Index Swap Bank Of America Na603698.SS10.88%
Nasdaq Biotechnology Index Swap Credit Suisse International603698.SS8.83%
Nasdaq Biotechnology Index Swap Goldman Sachs International603698.SS6.30%
Gilead SciencesGILD5.75%
View More Holdings


Hide News

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Other tickers mentioned: ARKG, IDNA, XBI
9 months ago - Zacks Investment Research

Last week witnessed a tug-of-war between bulls and bears.

Other tickers mentioned: CURE, CWEB, DIA, FNGO, FNGU, NEED, PILL ...
10 months ago - Zacks Investment Research